We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehensively analyze the effects of different drugs on intestinal flora. The study has important guiding significance for the treatment of patients with IBS-D.
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
the IBS symptom grade score
Timeframe: baseline
the quality of life score
Timeframe: baseline
the IBS symptom grade score
Timeframe: 2 weeks
the quality of life score
Timeframe: 2 weeks
the IBS symptom grade score
Timeframe: 12 weeks
the quality of life score
Timeframe: 12 weeks
16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota
Timeframe: 12 weeks
16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota
Timeframe: baseline
16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota
Timeframe: 2 weeks